newsfilter
← Latest News
GlobeNewswire·

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

  • Gabriele Cerrone, Executive Chairman & Founder of Tiziana Life Sciences, purchased 42,357 shares at $0.99 per share via Panetta Partners Ltd.
  • Cerrone's total holdings now stand at 44,814,587 shares, representing 34.93% of the company's issued share capital.
  • The company's lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody designed to stimulate T regulatory cells.
  • In an open-label Expanded Access Program, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis showed disease improvement or stability within 6 months.
  • A Phase 2a, randomized, double-blind, placebo-controlled, multicenter trial for foralumab in non-active secondary progressive multiple sclerosis is currently underway.
  • Foralumab is the only fully human anti-CD3 monoclonal antibody currently in clinical development.
  • Tiziana's intranasal delivery technology aims to improve efficacy, safety, & tolerability compared to intravenous administration.
  • The company holds patents for its alternative immunotherapy routes, with several applications pending.